The tumor cell-intrinsic cGAS-STING pathway is associated with the high density of CD8+ T cells after chemotherapy in esophageal squamous cell carcinoma

Esophagus. 2024 Apr;21(2):165-175. doi: 10.1007/s10388-024-01044-0. Epub 2024 Feb 7.

Abstract

Background: Chemotherapy has the potential to induce CD8+ T-cell infiltration in the tumor microenvironment (TME) and activate the anti-tumor immune response in several cancers including esophageal squamous cell carcinoma (ESCC). The tumor cell-intrinsic cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway has been known as a critical component for regulating immune cell activation in the TME. However, its effect on the infiltration of immune cells induced by chemotherapy in the ESCC TME has not been investigated.

Methods: We examined the effect of the tumor-cell intrinsic cGAS-STING pathway on the infiltration of CD8+ T cells induced by chemotherapy in ESCC using ESCC cell lines and surgically resected ESCC specimens from patients who received neoadjuvant chemotherapy (NAC).

Results: We found that chemotherapeutic agents, including 5-fluorouracil (5-FU) and cisplatin (CDDP), activated the cGAS-STING pathway, consequently inducing the expression of type I interferon and T-cell-attracting chemokines in ESCC cells. Moreover, the tumor cell-intrinsic expression of cGAS-STING was significantly and positively associated with the density of CD8+ T cells in ESCC after NAC. However, the tumor cell-intrinsic expression of cGAS-STING did not significantly impact clinical outcomes in patients with ESCC after NAC.

Conclusion: Our findings suggest that the tumor cell-intrinsic cGAS-STING pathway might contribute to chemotherapy-induced immune cell activation in the ESCC TME.

Keywords: 5-FU; CDDP; Chemotherapy; ESCC; cGAS–STING.

MeSH terms

  • CD8-Positive T-Lymphocytes
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Esophageal Neoplasms* / drug therapy
  • Esophageal Squamous Cell Carcinoma* / drug therapy
  • Fluorouracil / pharmacology
  • Fluorouracil / therapeutic use
  • Humans
  • Interferon Type I* / genetics
  • Interferon Type I* / metabolism
  • Interferon Type I* / therapeutic use
  • Nucleotidyltransferases / genetics
  • Nucleotidyltransferases / metabolism
  • Nucleotidyltransferases / therapeutic use
  • Tumor Microenvironment

Substances

  • Nucleotidyltransferases
  • Interferon Type I
  • Fluorouracil
  • Cisplatin